« Back
Home /
PF-8380

PF-8380

Item no.	TMO-T3631-10mM
Manufacturer	TargetMol
CASRN	1144035-53-9
Amount	1 mL x 10 mM (in DMSO)
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mL 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Oncology Metabolism Cholesterol & Lipid Metabolism Reagents & Chemicals Molecules By Organ Testicular & Prostate Cancer
Type	Molecules
Specific against	other
Citations	1. Gierse J, et al. J Pharmacol Exp Ther. 2010, 334(1):310-317.
Smiles	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	PDE inhibitor
Shipping Condition	Cool pack
Available
Manufacturer - Targets	PDE
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	478.33
Description	PF-8380 is an effective and orally available autotaxin inhibitor (IC50: 2.8 nM, in isolated enzyme assay; 101 nM, in the human whole blood). It modulates lysophosphatidic acid (LPA) levels in vivo/vitro by directly inhibiting autotaxin; reduces LPA levels both in plasma and at the site of inflammation.
Pathways	Metabolism
Bioactivity	Potent autotaxin inhibitor (IC50 = 2.8 nM in isolated enzyme assay; 101 nM in human whole blood). Modulates lysophosphatidic acid (LPA) levels in vivo and in vitro by directly inhibiting autotaxin; reduces LPA levels both in plasma and at site of inflammation. Orally available.
Receptor	Autotaxin

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T3631-10mM-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mL x 10 mM (in DMSO)

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question